Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | POLD1 | P28340 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810868 | 0.91 | TYMS (0.39) | POLBTYMSDUT | |
| SCHEMBL15810851 | 0.90 | P2RY2 (0.42) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL2888800 | 0.89 | TYMS (0.48) | TYMS | |
| SCHEMBL15810739 | 0.81 | POLA1 (0.39) | POLA1POLBPOLD1P2RY2P2RY6 | |
| SCHEMBL21277514 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL24414862 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL15810759 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL21277384 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL15810760 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 | |
| SCHEMBL625518 | 0.81 | P2RY2 (0.51) | P2RY2P2RY6P2RY4P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509716-B2 | Functional ligands to target vitamin C | Base Pair Biotechnologies, Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12338434-B1 | Methods and materials for discovery of functional ligands to molecular complexes | Base Pair Biotechnologies, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11970785-B2 | Methods and materials for multiplexed collections of functional ligands | Base Pair Biotechnologies, Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240110237-A1 | FUNCTIONAL LIGANDS | BASE PAIR BIOTECHNOLOGIES INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11725240-B2 | Functional ligands to opioids and opioid derivatives | Base Pair Biotechnologies, Inc. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116472276-A | Cytosine-type cross-linked nucleoside phosphoramidite crystal and method for producing same | 雅玛山酱油株式会社 | 2023-07-21 | — | — | CN | disclosed |
| US-20230111624-A1 | FUNCTIONAL LIGANDS TO TARGET MOLECULES | BASE PAIR BIOTECHNOLOGIES INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11608356-B1 | Functional ligands to colistin | Base Pair Biotechnologies, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220396795-A1 | FUNCTIONAL LIGANDS TO SARS-COV-2 SPIKE PROTEIN | BASE PAIR BIOTECHNOLOGIES INC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11427825-B2 | Functional ligands to drug compounds | Base Pair Biotechnologies, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20120121533-A1 | NUCLEIC ACID LIGANDS TO LL37 | BIOTEX, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120015359-A1 | METHODS FOR MOLECULAR DETECTION | BIOTEX, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110306054-A1 | METHODS FOR MOLECULAR DETECTION | BIOTEX, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8034569-B2 | Methods for molecular detection | BIOTEX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100240550-A1 | METHODS FOR SIMULTANEOUS GENERATION OF FUNCTIONAL LIGANDS | BIOTEX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100003688-A1 | METHODS FOR MOLECULAR DETECTION | BIOTEX, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090275130-A1 | BIOMIMETIC NUCLEIC ACIDS | BIOTEX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| EP-0815117-B1 | C-NUCLEOSIDE DERIVATIVES AND THEIR USE IN NUCLEIC ACID DETECTION | ROCHE DIAGNOSTICS GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| US-6320035-B1 | OLIGONUCLEOTIDE SYNTHESIZED FROM SPECIFIED NUCLEOSIDES HAVING AT LEAST ONE REPORTER GROUP BOUND TO PYRIMIDINE OR FURANOSE RING VIA LINKER GROUP WHICH CONTAINS ALKYNYL GROUP | ROCHE DIAGNOSTICS GMBH (DE) | 2001-11-20 | — | — | US | disclosed |
| US-6174998-B1 | FOR LABELLING AND DNA SEQUENCING | ROCHE DIAGNOSTICS GMBH (DE) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509716-B2 | Functional ligands to target vitamin C | PROC, HMOX2, H1-2 | POLA1 2495/4885POLB 2732/4885POLD1 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.